NRP1 and neoplasm: Regarding integrins, few data are available in which a PROTAC targeting PD-1/PD-L1 was designed using the tumor-penetrating iRGD peptide, binding intαvβ3 and inducing neuropilin-1-mediated transcytosis for deep tumor penetration but not considering integrins as therapeutic targets [113, 114].